CDK8 |
|
Available structures |
PDB |
Ortholog search: PDBe RCSB
|
List of PDB id codes |
3RGF, 4F6S, 4F6U, 4F6W, 4F70, 4F7J, 4F7L, 4F7N, 4F7S, 4G6L, 4CRL, 5HBH, 5CEI, 5FGK, 5HBE, 5BNJ, 5HBJ, 5HVY, 5HNB, 5I5Z |
|
|
Identifiers |
Aliases |
CDK8, K35, cyclin-dependent kinase 8, cyclin dependent kinase 8, IDDHBA |
External IDs |
OMIM: 603184 MGI: 1196224 HomoloGene: 55565 GeneCards: CDK8 |
|
Gene location (Mouse) |
|
Chr. |
Chromosome 5 (mouse) |
|
Band |
5|5 G3 |
Start |
146,168,040 bp |
End |
146,239,684 bp |
|
|
|
|
Wikidata |
|
Cell division protein kinase 8 is an enzyme that in humans is encoded by the CDK8 gene.
Function
The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK8 and cyclin C associate with the mediator complex and regulate transcription by several mechanisms. CDK8 binds to and/or phosphorylates several transcription factors, which can have an activating or inhibitory effect on transcription factor function. CDK8 phosphorylates the Notch intracellular domain,SREBP, and STAT1 S727. CDK8 also inhibits transcriptional activation by influencing turnover of subunits in the mediator complex tail module. In addition, CDK8 influences binding of RNA polymerase II to the mediator complex.
Clinical significance
CDK8 is a colorectal cancer oncogene: the CDK8 gene is amplified in human colorectal tumors, activating β-catenin-mediated transcription that drives colon tumorigenesis. However, CDK8 may not be oncogenic in all cell types, and indeed may act as a tumor suppressor in the notch and EGFR signaling pathways. Specifically, CDK8 promotes turnover of the notch intracellular domain, and inhibits EGFR signaling-driven cell fates in C. elegans. Thus, CDK8 may be an oncogene in cancers driven by Wnt/β-catenin signaling, but could instead be a tumor suppressor gene in cancers driven by notch or EGFR signaling. In addition, CDK8 promotes transcriptional activation mediated by the tumor suppressor protein p53, indicating that it may have an important role in tumor suppression Further research is needed to delineate the effects of CDK8 inhibition in different tissues, so for the time being, drugs targeting CDK8 for cancer treatment remain untested in humans.
An autosomal dominant syndrome has been described that is associated with mutations in the ATP binding pocket of the kinase domain. The clinical features include agenesis of the corpus callosum, mild to moderate intellectual disability, hypotonia, seizures, hearing or visual impairments, behavioral disorders, variable facial dysmorphism, congenital heart disease and ano-rectal malformations.
As a potential drug target
The natural product cortistatin A is a potent and selective inhibitor of CDK8 and CDK19. Inhibition of CDK8 and CDK19 with cortistatin A suppresses AML cell growth and has anticancer activity in animal models of AML by causing selective and disproportionate up regulation of super-enhancer-associated genes including the cell identity genes CEBPA and IRF8.
Interactions
Cyclin-dependent kinase 8 has been shown to interact with:
Further reading
-
Schultz SJ, Nigg EA (Oct 1993). "Identification of 21 novel human protein kinases, including 3 members of a family related to the cell cycle regulator nimA of Aspergillus nidulans". Cell Growth & Differentiation. 4 (10): 821–30. PMID 8274451.
-
Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E (Jun 1996). "Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II". Oncogene. 12 (12): 2631–40. PMID 8700522.
-
Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM (Apr 1997). "The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme". Molecular and Cellular Biology. 17 (4): 1817–23. doi:10.1128/MCB.17.4.1817. PMC 232028. PMID 9121429.
-
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD (May 1997). "BRCA1 is a component of the RNA polymerase II holoenzyme". Proceedings of the National Academy of Sciences of the United States of America. 94 (11): 5605–10. Bibcode:1997PNAS...94.5605S. doi:10.1073/pnas.94.11.5605. PMC 20825. PMID 9159119.
-
Neish AS, Anderson SF, Schlegel BP, Wei W, Parvin JD (Feb 1998). "Factors associated with the mammalian RNA polymerase II holoenzyme". Nucleic Acids Research. 26 (3): 847–53. doi:10.1093/nar/26.3.847. PMC 147327. PMID 9443979.
-
Cho H, Orphanides G, Sun X, Yang XJ, Ogryzko V, Lees E, Nakatani Y, Reinberg D (Sep 1998). "A human RNA polymerase II complex containing factors that modify chromatin structure". Molecular and Cellular Biology. 18 (9): 5355–63. doi:10.1128/MCB.18.9.5355. PMC 109120. PMID 9710619.
-
Sun X, Zhang Y, Cho H, Rickert P, Lees E, Lane W, Reinberg D (Aug 1998). "NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription". Molecular Cell. 2 (2): 213–22. doi:10.1016/S1097-2765(00)80131-8. PMID 9734358.
-
Rickert P, Corden JL, Lees E (Jan 1999). "Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases". Oncogene. 18 (4): 1093–102. doi:10.1038/sj.onc.1202399. PMID 10023686.
-
Gu W, Malik S, Ito M, Yuan CX, Fondell JD, Zhang X, Martinez E, Qin J, Roeder RG (Jan 1999). "A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation". Molecular Cell. 3 (1): 97–108. doi:10.1016/S1097-2765(00)80178-1. PMID 10024883.
-
Ito M, Yuan CX, Malik S, Gu W, Fondell JD, Yamamura S, Fu ZY, Zhang X, Qin J, Roeder RG (Mar 1999). "Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators". Molecular Cell. 3 (3): 361–70. doi:10.1016/S1097-2765(00)80463-3. PMID 10198638.
-
Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Näär AM, Erdjument-Bromage H, Tempst P, Freedman LP (Apr 1999). "Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex". Nature. 398 (6730): 824–8. Bibcode:1999Natur.398..824R. doi:10.1038/19783. PMID 10235266. S2CID 204992765.
-
Akoulitchev S, Chuikov S, Reinberg D (Sep 2000). "TFIIH is negatively regulated by cdk8-containing mediator complexes". Nature. 407 (6800): 102–6. Bibcode:2000Natur.407..102A. doi:10.1038/35024111. PMID 10993082. S2CID 4430185.
-
Ramanathan Y, Rajpara SM, Reza SM, Lees E, Shuman S, Mathews MB, Pe'ery T (Apr 2001). "Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences". The Journal of Biological Chemistry. 276 (14): 10913–20. doi:10.1074/jbc.M010975200. PMID 11278802.
-
Wang G, Cantin GT, Stevens JL, Berk AJ (Jul 2001). "Characterization of mediator complexes from HeLa cell nuclear extract". Molecular and Cellular Biology. 21 (14): 4604–13. doi:10.1128/MCB.21.14.4604-4613.2001. PMC 87123. PMID 11416138.
-
Di Pietro C, Rapisarda A, Bonaiuto C, Lizzio MN, Engel H, Amico V, Scalia M, Amato A, Grzeschik KH, Sichel G, Purrello M (May 1999). "Genomics of the human genes encoding four TAFII subunits of TFIID, the three subunits of TFIIA, as well as CDK8 and SURB7". Somatic Cell and Molecular Genetics. 25 (3): 185–9. doi:10.1023/A:1018897624615. PMID 11441538. S2CID 42316067.
-
Vogel L, Baratte B, Détivaud L, Azzi L, Leopold P, Meijer L (Apr 2002). "Molecular cloning and characterisation of p15(CDK-BP), a novel CDK-binding protein". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1589 (2): 219–31. doi:10.1016/S0167-4889(02)00175-1. PMID 12007796.
-
Crowley TE, Kaine EM, Yoshida M, Nandi A, Wolgemuth DJ (Aug 2002). "Reproductive cycle regulation of nuclear import, euchromatic localization, and association with components of Pol II mediator of a mammalian double-bromodomain protein". Molecular Endocrinology. 16 (8): 1727–37. doi:10.1210/me.2001-0353. PMID 12145330.
-
Sato S, Tomomori-Sato C, Banks CA, Sorokina I, Parmely TJ, Kong SE, Jin J, Cai Y, Lane WS, Brower CS, Conaway RC, Conaway JW (Apr 2003). "Identification of mammalian Mediator subunits with similarities to yeast Mediator subunits Srb5, Srb6, Med11, and Rox3" (PDF). The Journal of Biological Chemistry. 278 (17): 15123–7. doi:10.1074/jbc.C300054200. PMID 12584197. S2CID 41400940.
External links
|
Activity |
|
Regulation |
|
Classification |
|
Kinetics |
|
Types |
|